Effect of ethinylestradiol /drospirenone and dydrogesterone on body composition and lipid metabolism in overweight polycystic ovary syndrome patients

doi:10.3969/j.issn.1006-7795.2026.04.005

Abstract

Abstract: Objective To compare the effects of ethinyl estradiol/drospirenone(EE/DRSP) and dydrogesterone on body composition and lipid metabolism in overweight patients with polycystic ovary syndrome (PCOS). Methods A total of 160 overweight (24≤body mass index (BMI)< 28 kg/m2) women of reproductive age (18－40 years) who were diagnosed with PCOS and treated at the Department of Gynecological Endocrinology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, were recruited. The patients were randomly divided into two groups, with 80 patients in each group (EE/DRSP group, n=80; dydrogesterone group, n=80). Each group underwent three treatment cycles. The following parameters were observed before treatment and on days 2－5 of menstrual cycle after completing three cycles of treatment: anthropometric measurements (BMI, waist circumference, hip circumference); blood lipid parameters ［triglycerides (TG), total cholesterol (TC), high density lipoprotein-cholesterol (HDL-C), low density lipoprotein-cholesterol (LDL-C)］; and body composition parameters (lower limb muscle distribution coefficient, fat percentage, fat distribution).Results After three treatment cycles, waist circumference, hip circumference, BMI, fat distribution, fat percentage, TC and LDL-C in the EE/DRSP group were significantly reduced compared to baseline (P all<0.05). While HDL-C was significantly increased (P < 0.05). In the dydrogesterone group, BMI, waist circumference, and hip circumference, fat percentage, TC and LDL-C were significantly decreased (P<0.05). When the groups were compared, EE/DRSP led to more significant reductions in waist circumference, hip circumference, BMI, fat distribution, and fat percentage. It also resulted in a more significant increase in HDL-C and a more significant reduction in LDL-C (P all < 0.05). Conclusion While both EE/DRSP and dydrogesterone can improve the metabolic status of patients with polycystic ovary syndrome to some extent, EE/DRSP may offer more pronounced advantages in improving body composition and lipid metabolism.

Key words: polycystic ovary syndrome, ethinyl estradiol/drospirenone, dydrogesterone, body composition, lipid metabolism, overweight

CLC Number:

R711

Li Yanqiu , Ruan Xiangyan, Gu Muqing , Jiang Lingling , Zhang Mingzhen , Alfred O. Mueck. Effect of ethinylestradiol /drospirenone and dydrogesterone on body composition and lipid metabolism in overweight polycystic ovary syndrome patients[J]. Journal of Capital Medical University, 2026, 47(4): 665-672.

References

［1］Salari N, Nankali A, Ghanbari A, et al. Global prevalence of polycystic ovary syndrome in women worldwide: a comprehensive systematic review and meta-analysis［J］. Arch Gynecol Obstet, 2024, 310(3): 1303－1314.
［2］Amiri M, Hatoum S, Buyalos R P, et al. The influence of study quality, age, and geographic factors on PCOS Prevalence-a systematic review and meta-analysis［J］. J Clin Endocrinol Metab, 2025, 110(7): 2082－2103.
［3］Zhao H, Zhang J Q, Cheng X Y, et al. Insulin resistance in polycystic ovary syndrome across various tissues: an updated review of pathogenesis, evaluation, and treatment［J］. J Ovarian Res, 2023, 16(1): 9.
［4］Joham A E, Norman R J, Stener-Victorin E, et al. Polycystic ovary syndrome［J］. Lancet Diabetes Endocrinol, 2022, 10(9): 668－680.
［5］Ouyang X L, Zhou Q, Tang H, et al. Pathogenesis and treatment of obesity-related polycystic ovary syndrome［J］. J Ovarian Res, 2025, 18(1): 258.
［6］Teede H, Tassone E C, Piltonen T, et al. Effect of the combined oral contraceptive pill and/or metformin in the management of polycystic ovary syndrome: a systematic review with meta-analyses［J］. Clin Endocrinol, 2019, 91(4): 479－489.
［7］Lim S S, Davies M J, Norman R J, et al. Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis［J］. Hum Reprod Update, 2012, 18(6): 618－637.
［8］Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications［J］. Endocr Rev, 2012, 33(6): 981－1030.
［9］Demirci H, Menekse B, Ucgul E, et al. Impact of polycystic ovary syndrome on the atherogenic plasma index: a retrospective analysis［J］. BMC Endocr Disord, 2025, 25(1): 185.
［10］Anagnostis P, Paparodis R D, Bosdou J K, et al. Risk of type 2 diabetes mellitus in polycystic ovary syndrome is associated with obesity: a meta-analysis of observational studies［J］. Endocrine, 2021, 74(2): 245－253.
［11］Wu L M, Fang Q Y, Wang M L, et al. Effect of weight loss on pregnancy outcomes, neuronal-reproductive-metabolic hormones and gene expression profiles in granulosa cells in obese infertile PCOS patients undergoing IVF-ET［J］. Front Endocrinol, 2022, 13: 954428.
［12］Diakosavvas M, Oyebode O, Bhide P. Weight management strategies to reduce metabolic morbidity in women with polycystic ovary syndrome［J］. Curr Obes Rep, 2025, 14(1): 22.
［13］Wild R A, Rizzo M, Clifton S, et al. Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis［J］. Fertil Steril, 2011, 95(3):1073－9.e1－11.
［14］Mishra N, Mishra P, Kapoor V, et al. Lipid variations in different polycystic ovary syndrome phenotypes: a systematic review & meta-analysis［J］. Indian J Med Res, 2025, 161(5): 491－501.
［15］Rambaran N, Islam M S. Decoding androgen excess in polycystic ovary syndrome: roles of insulin resistance and other key intraovarian and systemic factors［J］. World J Diabetes, 2025, 16(7): 108789.
［16］Cussen L, McDonnell T, Miller C, et al. Polycystic ovary syndrome: origins and implications: polycystic ovary syndrome: the impact of androgen excess on metabolic health［J］. Reproduction, 2025, 170(2): e250102.
［17］Jafari K, Tajik N, Moini A, et al. Metabolic mediators of the overweight’s effect on infertility in women with polycystic ovary syndrome［J］. Sci Rep, 2025, 15(1): 16258.
［18］Yin Q Q, Liu Y, Zhang G Q, et al. Reduced mean platelet volume (MPV) as an inflammatory marker in Chinese women with polycystic ovary syndrome: a case-control study［J］. BMC Womens Health, 2025, 25(1): 484.
［19］Cassar S, Misso M L, Hopkins W G, et al. Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic-hyperinsulinaemic clamp studies［J］. Hum Reprod, 2016, 31(11): 2619－2631.
［20］Teede H J, Tay C T, Laven J J E, et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome［J］. J Clin Endocrinol Metab, 2023, 108(10): 2447－2469.
［21］Legro R S, Arslanian S A, Ehrmann D A, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline［J］. J Clin Endocrinol Metab, 2013, 98(12): 4565－4592.
［22］Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen［J］. Contraception, 2000, 62(1): 29－38.
［23］Gaspard U, Endrikat J, Desager J P, et al. A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles［J］. Contraception, 2004, 69(4): 271－278.
［24］Taneepanichskul S, Phupong V. Influence of a new oral contraceptive with drospirenone on lipid metabolism［J］. Gynecol Endocrinol, 2007, 23(6): 347－350.
［25］Gu M Q, Ruan X Y, Li Y Q, et al. Effect on the cardiovascular independent risk factor lipoprotein(a) in overweight or obese PCOS patients with ethinyl-estradiol/drospirenone alone or plus orlistat［J］. Gynecol Endocrinol, 2022, 38(7): 598－602.
［26］Hassan I T, Hussein E A, Abu Dulkareem M A, et al. Follicular and serum testosterone as a predictor of assisted reproductive technology outcomes in infertile polycystic ovarian syndrome patients［J］. Eurasian J Biosci, 2021, 14: 7315－7319.
［27］Hickey M, Higham J M, Fraser I. Progestogens with or without oestrogen for irregular uterine bleeding associated with anovulation［J］. Cochrane Database Syst Rev, 2012, 2012(9): CD001895.
［28］Spritzer P M. Contraception for women with polycystic ovary syndrome: dealing with a complex condition［J］. Rev Bras Ginecol Obstet, 2022, 44(4): 325－326.
［29］Han S J, Kim H, Ku S Y, et al. Comparison of resumption of ovulation after cessation of oral contraceptives and medroxyprogesterone acetate in women with polycystic ovary syndrome［J］. Gynecol Endocrinol, 2024, 40(1): 2309349.
［30］Nugent A G, Leung K C, Sullivan D, et al. Modulation by progestogens of the effects of oestrogen on hepatic endocrine function in postmenopausal women［J］. Clin Endocrinol, 2003, 59(6): 690－698.
［31］Ibáñez L, De Zegher F. Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity［J］. Clin Endocrinol Metab, 2004, 89(4): 1592－1597.
［32］Trouwborst I, Jardon K M, Gijbels A, et al. Body composition and body fat distribution in tissue-specific insulin resistance and in response to a 12-week isocaloric dietary macronutrient intervention［J］. Nutr Metab, 2024, 21(1): 20.
［33］Borst S E, Conover C F, Bagby G J. Association of resistin with visceral fat and muscle insulin resistance［J］. Cytokine, 2005, 32(1): 39－44.
［34］Matsui M, Fukuda A, Onishi S, et al. Insulin resistance: a marker for fat-to-lean body composition in Japanese adults［J］. Nutrients, 2023, 15(22): 4724.
［35］Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome［J］. Fertil Steril, 2004, 81(1): 19－25.
［36］Palomba S, Piltonen T T, Giudice L C. Endometrial function in women with polycystic ovary syndrome: a comprehensive review［J］. Hum Reprod Update, 2021, 27(3): 584－618.
［37］Kahleova H, Petersen K F, Shulman G I, et al. Effect of a low-fat vegan diet on body weight, insulin sensitivity, postprandial metabolism, and intramyocellular and hepatocellular lipid levels in overweight adults: a randomized clinical trial［J］. JAMA Netw Open, 2020, 3(11): e2025454.
［38］Oelkers W. Drospirenone, a progestogen with antimineralocorticoid properties: a short review［J］. Mol Cell Endocrinol, 2004, 217(1/2): 255－261.
［39］Mayeda E R, Torgal A H, Westhoff C L. Weight and body composition changes during oral contraceptive use in obese and normal weight women［J］. J Womens Health, 2014, 23(1): 38－43.
［40］Aksun S, Karaçoban L, Idilman I, et al. Impact of oral contraceptive use on muscle mass and strength in women with PCOS［J］. Endocrine, 2025, 89(2): 647－654.
［41］Stanczyk F Z, Hapgood J P, Winer S, et al. Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects［J］. Endocr Rev, 2013, 34(2): 171－208.
［42］Sitruk-Ware R. New progestagens for contraceptive use［J］. Hum Reprod Update, 2006, 12(2): 169－178.
［43］Yildizhan R, Gokce A I, Yildizhan B, et al. Comparison of the effects of chlormadinone acetate versus drospirenone containing oral contraceptives on metabolic and hormonal parameters in women with PCOS for a period of two-year follow-up［J］. Gynecol Endocrinol, 2015, 31(5): 396－400.

[1]	Li Kaiyin, Ruan Xiangyan, Wang Zecheng , Zhang Mingzhen, Liu Anming, Wang Yuejiao, Alfred O. Mueck, . Study on the effect of body composition on bone mineral density in perimenopausal and postmenopausal women [J]. Journal of Capital Medical University, 2026, 47(4): 680-685.
[2]	Zhao Yue, Ruan Xiangyan, Wang Yuejiao, Xie Dan, Jin Jing, Tian Xuanxuan, Zhang Xu, Zhang E, Zhu Jianguo, Zhang Zheng. Study on the correlation between the expression of key regulatory molecules and metabolic disorders in patients with polycystic ovary syndrome [J]. Journal of Capital Medical University, 2026, 47(4): 643-649.
[3]	Wang Qiqi, Guo Yushi, Li Yan. GDE1 contributes to lipid metabolic pathway dysregulation in type 2 chronic rhinosinusitis with nasal polyps [J]. Journal of Capital Medical University, 2026, 47(4): 722-729.
[4]	Jiang Lingling, Ruan Xiangyan, Li Yanqiu, Zhang Mingzhen, Wang Zecheng, Jin Jing, Tian Xuanxuan, Liu Anming, Alfred O. Mueck. Comparison of ethinyl-estradiol/drospirenone tablets alone or in combination with orlistat on ovulation recovery rate and metabolic indices in overweight/obese patients with polycystic ovary syndrome [J]. Journal of Capital Medical University, 2025, 46(4): 607-613.
[5]	Tian Xuanxuan, Ruan Xiangyan, Zhao Yue, Jin Jing, Liu Shunyu, Jiang Lingling. Effect of individualized lifestyle intervention on sexual function in obese patients with polycystic ovary syndrome [J]. Journal of Capital Medical University, 2025, 46(4): 614-619.
[6]	Zhao Yue, Ruan Xiangyan, Wang Yuejiao, Ma Jun, Jin Jing. Diagnostic value of multiple androgen indexes measured by LC-MS/MS for polycystic ovary syndrome [J]. Journal of Capital Medical University, 2024, 45(4): 602-608.
[7]	Jiang Lingling, Ruan Xiangyan, Li Yanqiu, Zhang Mingzhen, Wang Zecheng, Yang Yu , Liu Lili, Alfred O. Mueck. The impact of body composition on liver and kidney function and blood lipids in patients with polycystic ovary syndrome [J]. Journal of Capital Medical University, 2024, 45(4): 623-628.
[8]	Wang Zecheng, Ruan Xiangyan, Li Jing, Jiang Lingling, Alfred O.Mueck. he effect of iatrogenic premature ovarian insufficiency on lipid metabolism [J]. Journal of Capital Medical University, 2023, 44(4): 535-539.
[9]	Zhang Mingzhen, Ruan Xiangyan, Min Min, Alfred O. Mueck. Effect of Orlistat comprehensive intervention on lipoprotein(a) and glycolipid metabolism and hepatorenal function in overweight or obese patients with polycystic ovary syndrome [J]. Journal of Capital Medical University, 2023, 44(4): 544-549.
[10]	Tian Xuanxuan, Ruan Xiangyan, Jin Jing, Wang Juan, Cheng Jiaojiao. Investigation on awareness of the benefits from lifestyle intervention in patients with polycystic ovary syndrome [J]. Journal of Capital Medical University, 2023, 44(4): 555-560.